Cobra Biologics Expands Production Capacity

Cobra Biologics has installed a new Thermo Scientific 1000L HyClone Single-Use Bioreactor (SUB) at its center of excellence for mammalian antibody and recombinant protein production. The additional capacity is part of the company’s ongoing expansion plans and follows the signing of a new contract with a longstanding North American customer.
 
Cobra’s investment plan includes installing SUB technology across all three of its production sites for contract manufacturing services and the supply of commercial antibodies and recombinant proteins.
 
Peter Coleman, chief executive officer of Cobra Biologics, said, “Antibody and other recombinant protein production has been a strong growth area for our specialized manufacturing site. Cobra’s maxXpress cell line development and comprehensive analytics services are proving to be very attractive to customers. Demand is such that we have the confidence to invest for the future and we see this as just a stepping stone in the expansion of our capabilities at all three Cobra facilities.”
 
Brandon Pence, global director of marketing Cell Culture and BioProcessing at Thermo Fisher Scientific, said, “We are delighted to partner with Cobra Biologics in their continued expansion of their commercial operations. The combination of our application-focused design and collaborative approach to working with customers makes the Thermo Scientific Single-Use Bioreactor the system of choice for more than 85% of the top biopharma companies. Cobra’s decision to incorporate our industry-proven design will enable the company to confidently provide consistent and high quality manufacturing services to its biotech and biopharma customers.”